Scandinavian Journal of Immunology

Cover image for Vol. 85 Issue 4

Edited By: R. Jonsson and H-G. Ljunggren

Impact Factor: 2.27

ISI Journal Citation Reports © Ranking: 2015: 105/151 (Immunology)

Online ISSN: 1365-3083



Author Guidelines


PUBLICATION POLICY

Submission is considered on the conditions that papers are previously unpublished, and are not offered simultaneously elsewhere; that all authors have read and approved the content, and all authors have also declared all competing interests; and that the work complies with Ethical Policies of the Journal, and has been conducted under internationally accepted ethical standards after relevant ethical review.

EDITORIAL POLICIES AND PROCEDURES

Scandinavian Journal of Immunology, the official Journal of The Scandinavian Society for Immunology, published in print and online, provides an international forum for the publication of high quality original articles describing basic laboratory, translational and clinical investigations in immunology. Acceptance of papers is based on the originality of the observation or investigation, the quality of the work described, the clarity of presentation, and the relevance to our readership. When submitting a manuscript it is with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and has not been submitted elsewhere for print or electronic publication consideration.

The journal operates a stringent peer review process. All manuscripts will be reviewed by the Editors, members of the Editorial Board, or other expert reviewers. At the discretion of the Editors, the manuscript may be returned immediately without full review, if deemed not competitive or outside the realm of interests of the majority of the readership of the Journal. The decision (reject, invite revision, accept) letter will be conveyed through Scandinavian Journal of Immunology ScholarOne Manuscripts, coming directly from the Associate Editor who has assumed responsibility for the manuscript's review. Editorial decisions are based not just on technical merit of the work, but also on other factors such as the priority for publication and the relevance to the Journal's general readership. All papers are judged in relation to other submissions currently under consideration. Rebuttals to rejected manuscripts are strongly discouraged and requests for resubmission of rejected manuscripts are generally not granted.copyrigh

Publication ethics. Scandinavian Journal of Immunology is a member of the UK Committee on Publication Ethics and subscribes to its recommendations (Committee on Publication Ethics [COPE]: guidelines on good publication practice, www.publicationethics.org/international-standards-editors-and-authors). Best Practice Guidelines on Publication Ethics are also available from http://www.blackwellpublishing.com/publicationethics/ (Graf C, Wager E, Bowman A, et al., Int J Clin Pract 2007; 61 [suppl 152]: 126). The Editors reserve the right to reject a paper on ethical grounds. All authors are responsible for adhering to guidelines on good publication practice.

Pre-submission English-language editing.If you are not a native English speaker, we strongly recommend that you have your manuscript professionally edited before submission. A list of companies that will edit your manuscript for a fee can be found here http://authorservices.wiley.com/bauthor/english_language.asp. Professional editing is not compulsory, but will mean that reviewers are better able to read and assess your manuscript. Use of one of these companies does not guarantee acceptance or preference for publication in this journal.

NEW MANUSCRIPTS should be submitted online at the following URL: http://mc.manuscriptcentral.com/sji
See detailed submission procedures online at www.scandinavianimmunology.com.

The Central Office address below is to be used for (a) communication not covered by electronic submission and (b) for sending camera-ready figures for accepted papers:

Roland Jonsson, DMD, PhD
Editor-in-Chief, Scandinavian Journal of Immunology
Broegelmann Research Laboratory
The Laboratory Building, 5th Floor, Room 5385
N-5021 Bergen, Norway

Telephone: +47-55 97 46 48/49
Fax: +47-55 97 58 17
E-mail address:
sji@gades.uib.no

Please note: The Scandinavian Journal of Immunology e-mail address is for inquiries only; manuscripts must be submitted at the URL listed above.

Editorial office response. The successful online submission of the manuscript will be acknowledged via e-mail to the corresponding author. The corresponding author will receive the manuscript number, which should be cited in all correspondence happening outside of Scandinavian Journal of Immunology ScholarOne Manuscripts, the online submission and review system.

Categories of manuscripts
Regular manuscripts. Manuscripts submitted as Regular Articles are expected to be concise, well organized, and clearly written. Maximum length is 6000 words of text, excluding tables, figure legends, and references, and submissions are limited to a total of 7 figures. Submissions exceeding these limits will not necessarily be considered for review and might be returned to the author. Abstracts must not exceed 250 words and should be a single paragraph with no sub-headings. Acceptance of Regular Articles is based on the originality, definitiveness, and importance of the findings to the field of immunology. Manuscripts that have passed an initial screening by the Editors will normally be reviewed by two or more experts in the field. Detailed comments from the reviewers are generally returned to the authors. Manuscripts requiring extensive revision will be at a disadvantage for publication. Regular manuscripts will be published under the following scientific categories: Basic Immunology, Clinical Immunology and Immunological Methods.

Reviews. Review articles are highly desired and are generally solicited by the Editor-in-Chief or the Associate Editors. A review article should focus on a topic of broad scientific interest, on recent advances in diagnosis and therapy, or on some other timely subject relevant to immunology. Such articles must be concise and critical and include appropriate references to the literature. These manuscripts should not exceed 6000 words in length, must include abstracts of 250 words or fewer, and must have no more than 100 references. The use of tables and color figures to summarize critical points is encouraged. Review Articles are reviewed by the Editors and other expert reviewers before a final publication decision is made, and revisions may be required.

Letters to the Editor. Comments on published articles or current immunology topics are welcomed and will be published if appropriate. Letters should stay in the range of 300 to 500 words of text, 5 to 10 references, and 1 figure or table (if needed). Please include a brief title succinctly stating the topic of your Letter. Letters to the Editor are always screened, but may also be peer-reviewed or subjected to rebuttal by the authors of the initial article.

Supporting Information. Supporting Information can be a useful way for an author to include important but ancillary information with the online version of an article. Examples of Supporting Information include additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related nonessential multimedia files. Supporting Information should be cited within the article text, and a descriptive legend should be included. It is published as supplied by the author, and a proof is not made available prior ro publication; for these reasons, authors should provide any Supporting Information in the desired final format.

For further information on the recommended files types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp

Organization of manuscript
Organize the content of your manuscripts as follows: Title Page, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References, Tables, Figure Legends, and Figures. Other editorial requirements follow:

Author statement. Scandinavian Journal of Immunology no longer requires a signed Author Statement, but all authors are strongly encouraged to indicate their specific contributions to the submitted work. (See above under 'Scandinavian Journal of Immunology - definition of authorship.')

Declaration of commercial interest. For submitted papers that contain information affecting commercial products or potential products, we require that the authors declare any financial interest in the product or in potentially competing products. This policy applies to investors in and consultants to the involved commercial venture, as well as to persons holding patents relating to the product or potentially competing products. We also require that authors who are employees of companies whose commercial products are discussed in a submitted paper disclose the fact of their employment.
Please note: It is the responsibility of the corresponding author to review this policy with all authors and to collectively list the appropriate commercial relationships. In such cases, a footnote will accompany the published paper, describing the applicable relationship.

For work involving a biomedical product or potential product partially or wholly supported by corporate funding, an acknowledgement must accompany the paper stating: This study was supported (in part) by research funding from (company name) to (authors' initials).

Title page. This page should contain the following: Article title • Short title for running head (not to exceed 50 characters, including spaces between words) • Full and accurate names of all authors • Names of institutions in which work was done connected to the appropriate authors • Corresponding author’s full name, address, phone and fax number, and e-mail address • Word counts. You should also choose an appropriate scientific heading from among the following: Basic Immunology, Clinical Immunology, or Immunological Methods.

Abstract. The abstract should contain 250 words or fewer and state the rationale, objectives, findings, and conclusions of the study.

Acknowledgements. Acknowledge support received from individuals. Note about research grants and any other financial support.

References. We recommend the use of a tool such as Reference Manager for reference management and formatting.
Reference Manager reference styles can be searched for here: http://www.refman.com/support/rmstyles.asp
The references should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by arabic numerals [in brackets]. References cited only in tables or in legends to figures should be numbered in accordance with a sequence established by the first identification in the text of the particular table or illustration.

The titles of journals should be abbreviated according to the style used in Index Medicus.

Published abstracts can be used as references. Manuscripts accepted but not yet published can also be included in the references; designate the journal followed by 'in press' (in parentheses). Information from manuscripts submitted but not yet accepted should be cited in the text as 'unpublished observations' (in parentheses). 'Unpublished observations' and 'personal communications' may not be used as references, although references to written, not verbal, communications may be inserted (in parentheses) in the text.

Examples of correct forms of references are given below.

Journals
(1) Standard journal article. (List authors when six or fewer; when seven or more, list only first three and add et al.) Soter NA, Wasserman SI, Austen KF. Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor on anaphylaxis during cold challenge. N Engl J Med 1976;294:687-90.
(2) Corporate author. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended method for the determination of gamma-glutamyltransferase in blood. Scand J Clin Lab Invest 1976;36:119-25.
Books and other monographs
(3) Personal author(s). Osler AG. Complement: Mechanisms and Functions. Englewood Cliffs: Prentice Hall, 1976.
(4) Corporate author. American Medical Association Department of Drugs. AMA drug evaluations. 3rd edn. Littleton: Publishing Sciences Group, 1977.
(5) Chapter in book. Weistein L, Swartz MN. Pathogenic properties of invading micro-organisms. In: Sodeman WA Jr, Soderman WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-72.
Published proceedings paper
DuPont B. Bone marrow transplantation in severe combined immunodeficiency with an untreated MLC compatible donor. In: White HJ, Smith R, eds. Proceedings of the Third Annual Meeting of the International Society for Experimental Haematology. Houston: International Society for Experimental Haematology, 1974:44-6.

Footnotes and abbreviations. Do not use footnotes; instead, use parenthetical statements within text, but sparingly. Abbreviations should be defined at first mention and thereafter applied consistently throughout the article. Do not use nonstandard abbreviations or abbreviate terms appearing fewer than 3 times. Give the chemical name of a compound after the first use of the trivial name. The trivial name may follow throughout the article. Abbreviate units of measure only when used with numbers.

Tables. Each table should have a brief, specific, descriptive title, giving sufficient explanation to make the data intelligible without reference to the text. Number all tables and cite in numerical order in the text, using Arabic numerals.

Image acquisition and manipulation. The following information must be provided about the acquisition and processing of images: (1) make and model of microscope, (2) type, magnification, and numerical aperture of the objective lenses, (3) temperature, (4) imaging medium, (5) fluorochromes, (6) camera make and model, (7) acquisition software, and (8) any subsequent software used for image processing, with details about types of operations involved (eg, type of deconvolution, 3D reconstructions, surface or volume rendering, gamma adjustments, etc).
No specific feature within an image may be enhanced or moved. The grouping of images from different gels, fields, or exposures must be made explicit by the arrangement of the figure and in the text of the figure legend. Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image. Nonlinear adjustments (eg, gamma settings) must be disclosed in the figure legend. Digital images in manuscripts accepted for publication will be scrutinized for any indication of improper manipulation. As a result, the Editors may request the original data from the authors for comparison to the prepared figures. Cases of deliberate misrepresentation of data will be reported to the corresponding author's home institution or funding agency.

Preparation of figures. Cite figures in the text in numerical order using Arabic numerals. For peer-review submission, follow the online uploading instructions. Please save vector graphics (e.g. line artwork) in Encapsulated Postscript Format (EPS) and bitmap files (e.g. half-tones) in Tagged Image File Format (TIFF). Ideally, vector graphics that have been saved in metafile (.WMF) or pict (.PCT) format should be embedded within the body of the text file. Detailed information on our digital illustration standards is available at https://authorservices.wiley.com/author-resources/Journal-Authors/Prepare/manuscript-preparation-guidelines.html/index.html. Always send a hard copy of digitally supplied figures to the Central Editorial Office (details above).

Figure sizing for accepted manuscripts. For the print publication, lay out figures as compactly as is consistent with conveying the relevant data. Figures will be sized to fit the smallest possible space, but in order to prevent radical changes in figure content, prepare the figures in one of two sizes: 8.0 cm (1-column width) or, if necessary, 11.5 cm (11/2 column width). These instructions do not apply to figures submitted for online review and prepublication.

Figure legends. All legends must begin with a short descriptive sentence that sums up the intent and content of the data contained in the figure. This sentence should be in boldfont. A more detailed explanation of the data contained in the figure and/or its parts should follow. The detailed description should be in Roman type (ie, not in boldfont).

Color charges. Scandinavian Journal of Immunology offers authors the opportunity to reproduce figures in colour free of charge, where use of colour is deemed necessary.

Display of sequences. Prepare sequences as figures, not tables. This will ensure that proper alignment is preserved.
Submission of sequences to GenBank. Original DNA sequences reported in Scandinavian Journal of Immunology must also be submitted to GenBank. Instructions for submission can be found at the following address: http://www.ncbi.nlm.nih.gov/Genbank/. An accession number should be supplied parenthetically at a relevant location in text.

Human and murine genes. For human genes, use genetic notation and symbols approved by the HUGO Nomenclature Committee. Approved gene symbols should be obtained prior to submission from the HUGO Nomenclature Committee, nome@galton.ucl.ac.uk. For nomenclature guidelines, see White et al., 'Guidelines for Human Gene Nomenclature' [Genomics, 45, 468-471 (1997)]. The Gene Name Proposal form may be completed on the Nomenclature Web page: http://www.gene.ucl.ac.uk/nomenclature. Use ISCN nomenclature for cytogenetics notation [Mitelman, F. (ed.) ISCN 1995: An International System for Human Cytogenetic Nomenclature, S. Karger, Basel]. Human gene names and loci should be written in uppercase italics and Arabic numerals. Protein products are not italicized.

For mouse strain and genetic nomenclature, refer to the International Committee on Standardized Genetic Nomenclature for Mice: http://www.informatics.jax.org/nomen/. New symbols and names for genes should be obtained prior to submission through the online symbol registry form at: http://www.informatics.jax.org/nomen/nomen_submit_form.shtml.

Microarray databases. Scandinavian Journal of Immunology supports the efforts of the Microarray Gene Expression Data Society to standardize the presentation of microarray data, and we recommend that authors follow their guidelines and checklist (http://www.mged.org/Workgroups/MIAME/miame_checklist.html). In addition, the Journal strongly recommends the supplemental microarray data be deposited in a public database such as Gene Expression Omnibus (or GEO, at http://www.ncbi.nlm.nih.gov/geo/) or Array Express (http://www.ebi.ac.uk/arrayexpress/) or submitted for peer-review with the initial submission of the manuscript.

Data sharing. Scandinavian Journal of Immunology supports the efforts to encourage open sharing of publication-related data. Scandinavian Journal of Immunology adheres to the beliefs that authors should include in their publications the data, algorithms, or other information that is central or integral to the publication or make it freely and readily accessible; use public respositories for data whenever possible; and make patented material available under a license for research use. For more information, see the NAS website: http://books.nap.edu/books/0309088593/html/1.html

Distribution of reagents. The Editors of Scandinavian Journal of Immunology has adopted the policy that any readily renewable resources mentioned in a Journal article not already obtainable from commercial sources shall be made available to all qualified investigators in the field. The policy stems from the long-standing scientific principle that authenticity requires reproducibility. Publication in Scandinavian Journal of Immunology constitutes a de facto acceptance of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and genomic clones, cell lines, and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro work reported) of novel protein reagents are also considered easily transferable.

Although the Editors appreciate that many of the reagents mentioned in Scandinavian Journal of Immunology are proprietary or unique, neither condition is considered adequate grounds for deviation from this policy. Suitable material transfer agreements can be drawn up between the provider and requester, but if a reasonable request is turned down and submitted to the Editor-in-Chief, the corresponding author will be held accountable. The consequence for noncompliance is simple: the corresponding author will not publish in Scandinavian Journal of Immunology for the following 3 years.

Guidelines for stem cell research. Research with embryonic stem cells should adhere to the guidelines established by the National Academy of Sciences, as published in the National Academy Press, at http://nap.edu/books/0309096537/html.

Proofs. The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site: Adobe Reader Download. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately.


Word counts. All manuscripts must include a total text word count and an abstract word count on the title page of the manuscript. The total text word count does not include title page, figure legends, references, or tables. Only under exceptional circumstances will papers containing more than 6000 words be considered, but under no circumstances will abstracts longer than 250 words be published.

Revised manuscripts. In many cases, authors will be invited to make revisions to their manuscript. A revised manuscript should preferably be received by the responsible Associate Editor within 3 months of the date on the decision letter or it will be considered a new submission. An extension can sometimes be negotiated with the Associate Editor.

Fees and reprints
Processing fee. There are no processing fees for papers submitted to Scandinavian Journal of Immunology.

Page charges and reprint fees.

Page charges. There are no page charges for any type of articles published in Scandinavian Journal of Immunology. Exception might be supplements.

Reprint prices. A schedule of prices will be provided on the Reprint Order Form. Reprints must be ordered at the time the page proofs are reviewed. Later orders, especially of Reprints with color images, will be much more costly.

Additional information
Cover illustrations. Cover illustrations are chosen by the Editor-in-Chief. Authors who submit a manuscript are encouraged to include a color image they consider suitable for the cover of Scandinavian Journal of Immunology (author must own copyright to the image.) Add a brief caption explaining the content of the figure. Cover illustrations are published without charge to the author, but authors may be charged for color figures used within their article.

Announcements Announcements of meetings that are of interest to the readers of Scandinavian Journal of Immunology should be sent to the Editor-in-Chief at least 3 months before the first day of the month of issue. Fees for announcements vary depending on their size and the number of insertions. Prices may be obtained by contacting the Scandinavian Journal of Immunology Publishing Office (telephone: +44 1865 776868; fax: +44 1865 714591).

Advertisements/classified ads. Advertisements and classified ads should be sent to Scandinavian Journal of Immunology’s advertising representative, Kevin Phillips (Kephillips@wiley.com).

Copyright If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below: CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA): Creative Commons Attribution License OAA Creative Commons Attribution Non-Commercial License OAA Creative Commons Attribution Non-Commercial -NoDerivs License OAA To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

OnlineOpen. OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

Scandinavian Journal of Immunology collaborates with two Wiley’s open access journals, Immunity, Inflammation and Disease and Clinical Case Reports, to enable rapid publication of good quality research that we are unable to accept for publication in Scandinavian Journal of Immunology. Authors of rejected manuscripts will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editors of the appropriate open access journal. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editors of Immunity, Inflammation and Disease and Clinical Case Reports will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Immunity, Inflammation and Disease and Clinical Case Reports are open access journals, and article publication fees apply. For more information please go to www.immunityinflammationdisease.com or www.clinicalcasesjournal.com.

SEARCH

SEARCH BY CITATION